A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women

BACKGROUND:Tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) is an objective long-term adherence measure, but data are limited on its ability to predict virologic suppression (VS) in people on antiretroviral (ARV) treatment. There are also no data comparing DBS TFV-DP with plasma ARV concent...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of acquired immune deficiency syndromes (1999) 2019-07, Vol.81 (3), p.311-318
Hauptverfasser:	Phillips, Tamsin K, Sinxadi, Phumla, Abrams, Elaine J, Zerbe, Allison, Orrell, Catherine, Hu, Nai-Chung, Brittain, Kirsty, Gomba, Yolanda, Norman, Jennifer, Wiesner, Lubbe, Myer, Landon, Maartens, Gary
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenine - analogs & derivatives Adenine - blood Adenine - therapeutic use Adhesion Adult AIDS/HIV Alkynes Anti-HIV Agents - blood Anti-HIV Agents - therapeutic use Anti-Retroviral Agents - blood Anti-Retroviral Agents - therapeutic use Antiretroviral agents Antiretroviral drugs Antiretroviral therapy Assaying Benzoxazines - blood Benzoxazines - therapeutic use Blood Cross-Sectional Studies Cyclopropanes Efavirenz Emtricitabine Emtricitabine - therapeutic use Female HIV Infections - drug therapy Humans Logistic Models Organophosphates - blood Organophosphates - therapeutic use Plasma Regression analysis Self Report South Africa Tenofovir Tenofovir - blood Tenofovir - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	BACKGROUND:Tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) is an objective long-term adherence measure, but data are limited on its ability to predict virologic suppression (VS) in people on antiretroviral (ARV) treatment. There are also no data comparing DBS TFV-DP with plasma ARV concentrations as predictors of VS. METHODS:Women who were on a first-line regimen of tenofovir, emtricitabine, and efavirenz (EFV) were enrolled in a cross-sectional study. Plasma EFV and tenofovir (TFV), DBS TFV-DP assays, and 30-day self-reported adherence were evaluated as predictors of VS (
ISSN:	1525-4135 1944-7884
DOI:	10.1097/QAI.0000000000002032